Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, Randomized, Double-Blind, 3-Arm, Parallel Study to Compare the Pharmacokinetics, Safety and Tolerability of AVT02 to EU-approved and US-licensed Humira® Administered as a Single Dose (40 mg Subcutaneous Injection) in Healthy Adult Volunteers (ALVOPA D FIRST)

NCT03849313 is registered in ClinicalTrials.gov with Alvotech Swiss AG as lead sponsor.

NCT NCT03849313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03849313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, Randomized, Double-Blind, 3-Arm, Parallel Study to Compare the Pharmacokinetics, Safety and Tolerability of AVT02 to EU-approved and US-licensed Humira® Administered as a Single Dose (40 mg Subcutaneous Injection) in Healthy Adult Volunteers (ALVOPA D FIRST)
Lead sponsor
Alvotech Swiss AG
Phase
Phase 1
Overall status
Completed
Start date
March 20, 2019
Completion date
February 17, 2020
Enrollment
390 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers